Unveiling Pancreatic Cancer's Sweet Defense: A New Immunotherapy Target
Pancreatic cancer, a formidable foe in the battle against cancer, has long evaded immunotherapy. A recent study from Northwestern University reveals a fascinating mechanism behind this resistance. Researchers led by Mohamed Abdel-Mohsen, PhD, have uncovered how pancreatic tumor cells employ a clever sugar-based disguise to evade immune attack. This discovery not only sheds light on a new immune-evasion strategy but also presents a promising therapeutic approach to counter it.
"It took our team six years to unravel this mystery," Abdel-Mohsen shared. "Pancreatic cancer essentially wears a sugar-coated mask. This sugar molecule, sialic acid, tricks the immune system into thinking the cancer cells are normal, preventing an attack." This sugar shield is a classic example of a wolf in sheep's clothing.
The Sugar Shield: A Barrier to Immune Attack
Pancreatic ductal adenocarcinoma (PDAC), the most common pancreatic cancer, remains one of the deadliest, with a five-year survival rate of less than 13%. One of the key challenges in treating PDAC is its immunosuppressive microenvironment, which hinders immune cells from recognizing and eliminating tumor cells. Abdel-Mohsen's research identifies a crucial component of this puzzle: PDAC cells are adorned with sialic acid sugars attached to the integrin α3β1 protein. These sugars bind to Siglec-10, a receptor on immune cells, acting as a glyco-immune checkpoint.
"When Siglec-10 encounters sialic acid, it sends a 'stand down' signal to the immune cells," Abdel-Mohsen explained. "It tells them there's nothing to worry about. As a result, macrophages, which are crucial for cancer cell destruction, don't attack, allowing the cancer to grow unchecked."
A Novel Immune Checkpoint for Pancreatic Cancer
Previous studies had hinted at similar sugar-based mechanisms in breast and ovarian cancers, involving Siglec-10 and a different ligand, CD24. However, pancreatic tumors typically lack CD24. Abdel-Mohsen's team, utilizing advanced techniques like flow cytometry, mass spectrometry, and live imaging, discovered that PDAC cells use integrin α3β1 as a novel Siglec-10 binding partner.
This finding highlights a broader principle: different cancers may employ distinct sugar-coated disguises to exploit the same immune checkpoint pathway. "We were surprised to find that the same immune receptor, Siglec-10, is manipulated by a completely different ligand in pancreatic cancer," Abdel-Mohsen noted. "It demonstrates cancer's remarkable adaptability in deceiving our immune system."
Reactivating the Immune System
To counter this sugar-based deception, Abdel-Mohsen's team developed an antibody that blocks Siglec-10 on myeloid cells, preventing it from binding to the sialic-acid-coated integrin on tumor cells. This blockade reactivates macrophages, enabling them to directly attack tumor cells through phagocytosis and "teach" T cells how to recognize and destroy cancer. "Myeloid cells are the teachers of the immune system," Abdel-Mohsen emphasized. "If they're silenced, T cells can't learn to attack the tumor. But by blocking Siglec-10, we awaken these teachers."
In laboratory experiments, the Siglec-10 antibody alone significantly reduced pancreatic tumor growth in mice by 36-40%. The next step, according to Abdel-Mohsen, is to combine this antibody with existing immunotherapies that target T cells, such as PD-1 or PD-L1 inhibitors, to activate both arms of the immune response simultaneously.
"Current immunotherapies primarily focus on T cells," he explained. "But if the teachers are asleep, the T cells can't learn. Our approach wakes up the teachers, while other drugs activate the students. Together, they can launch a more potent attack."
Beyond Pancreatic Cancer
While this study focused on pancreatic cancer, Abdel-Mohsen believes the mechanism may extend to other 'cold' tumors resistant to immunotherapy, such as glioblastoma. "Many cancers use this sugar trick," he said. "They cover themselves with sialic acid, often on different proteins. Even virally infected cells employ similar sugar disguises to evade the immune system."
This observation underscores the importance of glycobiology, a field studying complex cell surface sugars, and its underappreciated role in immune regulation. "Glycobiology and glyco-immunology are still not mainstream," Abdel-Mohsen noted. "However, we repeatedly observe that these sugar interactions are crucial in determining the immune system's attack or ignorance. Ignoring them has limited our understanding of immune evasion."
Moving Towards Clinical Trials
Abdel-Mohsen and his team are collaborating with clinicians at Northwestern's Lurie Cancer Center to translate their findings into clinical trials. "We're conducting preclinical studies to ensure the antibody's safety and effectiveness," he said. "Ultimately, our goal is to combine this approach with chemotherapy or existing immunotherapies for a comprehensive treatment strategy."
Abdel-Mohsen emphasized that pancreatic cancer won't succumb to a single therapy. "There won't be a magic bullet," he stated. "Instead, an arsenal of solutions working together will outsmart the tumor."
The implications extend far beyond pancreatic cancer. Targeting sugar-based immune checkpoints like Siglec-10 could open new therapeutic avenues for diseases with limited effective treatments. "By targeting glycans, we're unlocking a new layer of immune regulation," Abdel-Mohsen concluded. "This could be the key to bringing immunotherapy success to pancreatic cancer and potentially other stubborn cancers."
